Back to top

Image: Bigstock

Should You Continue to Hold ALGN Stock in Your Portfolio?

Read MoreHide Full Article

Key Takeaways

  • ALGN has gained 25.4% in a year, outperforming its industry and the S&P 500 amid Invisalign expansion.
  • ALGN's younger patient shipments and North American DSO aligner volumes rose at double-digit rates.
  • Currency headwinds cut ALGN's Q3 revenues by $5 million, while competition pressures pricing.

Align Technology (ALGN - Free Report) continues to broaden the clinical reach of the Invisalign portfolio beyond traditional adult and teen alignment. The company is focused on increasing adoption of digital dentistry through DSO relationships, doctor support programs and consumer engagement. However, fierce competitive pressure and currency movements continue to pose risks for Align Technology’s results.

Over the past year, this Zacks Rank #3 (Hold) stock has gained 25.4% compared with the 23.3% rise of the industry and the S&P 500 composite’s 13.8% growth.

The renowned medical device company has a market capitalization of $11.86 billion. ALGN projects a long-term estimated earnings growth rate of 8.4% compared with the 9.4% rise of the industry. Its earnings surpassed estimates in each of the trailing four quarters, the average surprise being 7.2%.

Let’s delve deeper.

Upsides for ALGN Stock

Invisalign Business Expansion: Align Technology continues to broaden the clinical reach of Invisalign beyond traditional adult and teen alignment. Invisalign Palatal Expander, Invisalign First and Invisalign with Mandibular Advancement featuring Occlusal Blocks expand treatment options for younger patients and more complex cases. The company has extended these products across several EMEA and APAC markets, including China, India, Malaysia and Turkey. In the third quarter of 2026, younger patient shipments increased at a double-digit rate in international markets, supported by teen demand across APAC and EMEA. 

Beyond orthodontics, its Advanced Restorative Treatment initiative connects tooth alignment with restorative planning through exocad software. The NXT direct 3D-printing platform, Specifix attachments and Invisalign Sports Guard pilot further extend potential applications. 

Strategic Alliances: Align Technology continues to use dental service organizations, doctor engagement programs and consumer initiatives to increase Invisalign adoption. The company has established DSO relationships, particularly in the United States, and previously expanded partnerships with Smile Doctors and Heartland Dental. These relationships remain important because DSOs provide access to multiple practices and can support consistent treatment workflows. 

In the third quarter of 2026, North American DSO Clear Aligner shipments increased at a double-digit rate across orthodontists and GP dentists. Align is extending patient financing through its Healthcare Finance Direct collaboration and evaluating additional options through a CareCredit pilot. Its SHIFT Happens consumer campaign is designed to increase adult Invisalign awareness and treatment consideration.

 

Zacks Investment Research
Image Source: Zacks Investment Research

Concerns for ALGN

Currency Volatility: Foreign exchange remains a recurring source of earnings volatility because Align Technology generates a substantial portion of its revenues outside the United States. Currency effects during the third quarter reduced reported revenues by approximately $5 million, or 0.5%, year over year. Both GAAP and non-GAAP diluted EPS faced an unfavorable year-over-year impact of approximately 24 cents each. As Align expands internationally, managing foreign currency exposure remains critical, particularly as geographic and product mix shifts also affect reported ASPs and profit margins.

Competitive Landscape: Align Technology competes with traditional wires and brackets as well as lower-priced clear aligner alternatives. Management has responded with products spanning more case complexities and price points, including offerings with fewer or no additional aligners. Competition can influence discounts, product mix, doctor adoption and treatment pricing, limiting the pace of revenues and ASP expansion.

ALGN Stock’s Estimate Trend

The Zacks Consensus Estimate for Align Technology’s 2026 earnings per share (EPS) has moved south by 1.5% to $11.12 in the past 30 days.

The same for 2026 revenues is pegged at 4.13 billion. This suggests a 2.2% rise from the year-ago reported number.

Key Picks

Some better-ranked stocks in the broader medical space are Phibro Animal Health (PAHC - Free Report) , IDEXX Laboratories (IDXX - Free Report) and Globus Medical (GMED - Free Report) . 

Phibro Animal Health has an earnings yield of 10.6% compared with the industry’s 2.8% yield. Shares of the company have lost 28.1% compared with the industry’s 19.1% decline over the past year. PAHC’s earnings outpaced estimates in three of the trailing four quarters and matched on one occasion, the average surprise being 12.43%. 

PAHC carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

IDEXX Laboratories, currently holding a Zacks Rank #2, has an earnings yield of 2.2% against the industry’s negative 2.3% yield. Its earnings beat estimates in each of the trailing four quarters, the average surprise being 5.5%. IDXX’s shares have plunged 4.8% against the industry’s 3% growth over the past year.

Globus Medical, presently carrying a Zacks Rank #2, has an earnings yield of 7% against the industry’s negative 2.3% yield. Its earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 16.2%. GMED’s shares have lost 17.7% against the industry’s 3% growth over the past year.

Published in